VRTX:NSD-Vertex Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 483.31

Change

+3.52 (+0.73)%

Market Cap

USD 123.21B

Volume

1.28M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-13.87 (-1.99%)

USD 76.39B
ARGX argenx NV ADR

-2.06 (-0.33%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

-3.22 (-1.30%)

USD 31.94B
ONC BeiGene, Ltd.

-26.27 (-9.67%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.22 (+0.65%)

USD 18.65B
SMMT Summit Therapeutics PLC

-1.56 (-7.54%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-10.02 (-3.13%)

USD 14.37B
INCY Incyte Corporation

-3.24 (-4.41%)

USD 14.22B
INSM Insmed Inc

-5.26 (-6.45%)

USD 13.70B
BMRN Biomarin Pharmaceutical Inc

-0.14 (-0.20%)

USD 13.58B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

+0.46 (+-1.18%)

USD 0.08B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 8.43 % 0.00 %

-0.11 (-1.18%)

USD 5.16M
MSGR 8.22 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 7.99 % 0.00 %

-0.13 (-1.18%)

N/A
BTEC:SW iShares Nasdaq US Biotech.. 7.95 % 0.00 %

-0.01 (-1.18%)

N/A
UBIO 6.52 % 0.95 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.49 % 0.00 %

N/A

N/A
ZWHC:CA BMO Covered Call Health C.. 5.16 % 0.00 %

N/A

N/A
LIFE-U:CA Evolve Global Healthcare .. 5.00 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.94 % 0.00 %

-0.16 (-1.18%)

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.91 % 0.00 %

-0.27 (-1.18%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

+0.09 (+-1.18%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

+0.59 (+-1.18%)

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 4.76 % 0.00 %

+0.09 (+-1.18%)

N/A
XT2D:LSE db x-trackers S&P 500 2x .. 4.65 % 0.00 %

-0.01 (-1.18%)

USD 0.05B
XSD2:LSE db x-trackers ShortDAX x2.. 4.39 % 0.00 %

-2.99 (-1.18%)

USD 0.10B
HEAL:CA 3.39 % 0.00 %

N/A

N/A
CDNA:CA CI Bio-Revolution Index E.. 2.75 % 0.00 %

+0.03 (+-1.18%)

CAD 6.70M
BIOT:SW L&G Pharma Breakthrough U.. 2.68 % 0.00 %

N/A

N/A
UPWD 2.43 % 0.00 %

N/A

N/A
POWA Invesco Bloomberg Pricing.. 2.11 % 0.00 %

-0.80 (-1.18%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.10 % 0.00 %

N/A

N/A
SAGP The Advisorsa Inner Circl.. 2.09 % 0.00 %

+0.04 (+-1.18%)

USD 0.04B
TDOC:CA TD Global Healthcare Lead.. 2.05 % 0.00 %

+0.20 (+-1.18%)

CAD 0.08B
CAPG:CA Capital Group Global Equi.. 1.94 % 0.00 %

-0.31 (-1.18%)

CAD 0.04B
XLVE:CA 1.93 % 0.00 %

N/A

N/A
ESMV iShares ESG MSCI USA Min .. 1.48 % 0.00 %

-0.10 (-1.18%)

USD 8.61M
FLXU:SW Franklin U.S. Equity UCIT.. 1.17 % 0.00 %

N/A

N/A
QQEQ:CA Invesco NASDAQ 100 Equal .. 1.13 % 0.00 %

-0.06 (-1.18%)

CAD 0.01B
THNZ:XETRA 1.03 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

-2.12 (-1.18%)

USD 0.39B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-2.14 (-1.18%)

USD 0.06B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.67 (+-1.18%)

USD 3.30M
DEF 0.00 % 0.59 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

-4.01 (-1.18%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-2.79 (-1.18%)

USD 6.39B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.77 (+-1.18%)

USD 0.06B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-8.59 (-1.18%)

USD 0.77B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-1.22 (-1.18%)

N/A
QQXT First Trust NASDAQ-100 Ex.. 0.00 % 0.60 %

-0.83 (-1.18%)

USD 0.11B
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

-0.50 (-1.18%)

USD 0.19B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.49 (-1.18%)

USD 0.05B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+-1.18%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.03 (-1.18%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-2.40 (-1.18%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+-1.18%)

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-3.11 (-1.18%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

-0.37 (-1.18%)

N/A
AIEQ Amplify ETF Trust 0.00 % 0.75 %

-0.97 (-1.18%)

USD 0.11B
HWWA:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

+0.12 (+-1.18%)

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE 0.00 % 0.00 %

N/A

N/A
HWWD:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

+0.43 (+-1.18%)

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

-0.05 (-1.18%)

USD 0.52B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.23 (+-1.18%)

N/A
FLXU:F Franklin LibertyShares IC.. 0.00 % 0.00 %

-0.14 (-1.18%)

N/A
SM8T:F 0.00 % 0.00 %

N/A

N/A
XAIN:F Xtrackers - MSCI Indonesi.. 0.00 % 0.00 %

+0.55 (+-1.18%)

USD 0.04B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.01 (-1.18%)

USD 0.52B
DBPD:XETRA Xtrackers ShortDAX x2 Dai.. 0.00 % 0.00 %

-0.03 (-1.18%)

USD 0.13B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.03 (-1.18%)

USD 0.02B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

+0.05 (+-1.18%)

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

-12.90 (-1.18%)

USD 8.65M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

+0.04 (+-1.18%)

USD 8.62M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.50 (-1.18%)

USD 0.04B
FFND The Future Fund Active ET.. 0.00 % 0.00 %

-0.37 (-1.18%)

USD 0.06B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.02% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.02% 88% B+ 91% A-
Trailing 12 Months  
Capital Gain 13.98% 83% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.98% 83% B 72% C
Trailing 5 Years  
Capital Gain 97.01% 90% A- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.01% 90% A- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 16.88% 65% D 71% C-
Dividend Return 16.88% 65% D 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.62% 91% A- 68% D+
Risk Adjusted Return 63.39% 97% N/A 84% B
Market Capitalization 123.21B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector